I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
It is used as a pharmaceutical intermediate.
Morihiro Mitsuya.; Kensuke Kobayashi.; Kumiko Kawakami.; Atsushi Satoh.; Yoshio Ogino.; Taro Kakikawa.; Norikazu Ohtake.; Toshifumi Kimura.; Hiroyasu Hirose.; Akio Sato.; Tomosige Numazawa.;Takuro Hasegawa.; Kazuhito Noguchi.; Toshiaki Mase. A Potent, Long-Acting, Orally Active (2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetamide:? A Novel Muscarinic M3 Receptor Antagonist with High Selectivity for M3 over M2 Receptors. J. Med. Chem. 2000, 43 (26),5017-5029.
Evan G. Robertson.; Matthew R. Hockridge.; Peter D. Jelfsa.; John P. Simons. IR-UV ion-depletion and fluorescence spectroscopy of2-phenylacetamide clusters: hydration of a primary amide. Phys. Chem. Chem. Phys. 2001, 3 (5),786-795.
Gefahrenhinweise (EU): H302-H319
Harmful if swallowed. Causes serious eye irritation.
Do not breathe dust/fume/gas/mist/vapours/spray. Obtain special instructions before use. Wear eye/face protection. IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.